![Pfizer Inc. on Twitter: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older. Pfizer Inc. on Twitter: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older.](https://pbs.twimg.com/media/E0x-tDpXIAIIv4g.jpg)
Pfizer Inc. on Twitter: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older.
![NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration | ISU Research Park NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration | ISU Research Park](https://www.isupark.org/wp-content/uploads/2017/02/NewLink_Logo_RGB.jpg)
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration | ISU Research Park
![Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne](https://cureduchenne.org/wp-content/uploads/2022/10/SYNTHERA-2WEB-POST-HEADER.png)
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne
![CALL FOR PAPERS – ACL Rolling Review – A new initiative of the Association for Computational Linguistics CALL FOR PAPERS – ACL Rolling Review – A new initiative of the Association for Computational Linguistics](http://aclrollingreview.org/images/ARR.png)
CALL FOR PAPERS – ACL Rolling Review – A new initiative of the Association for Computational Linguistics
![Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19 Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19](https://mma.prnewswire.com/media/1594541/Merck_Canada_Inc__Merck_Canada_Initiates_Rolling_Submission_to_H.jpg?p=facebook)
Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19
Reata Pharmaceuticals on Twitter: "We're excited to announce that we have completed the rolling New Drug Application (NDA) for omaveloxolone." / Twitter
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Sage Therapeutics,
![Madrigal Pharmaceuticals Initiates NDA Rolling Submission for Breakthrough Liver Fibrosis Treatment - MyChesCo Madrigal Pharmaceuticals Initiates NDA Rolling Submission for Breakthrough Liver Fibrosis Treatment - MyChesCo](https://i0.wp.com/www.mychesco.com/wp-content/uploads/2021/06/Madrigal-Pharmaceuticals.jpg?fit=735%2C400&ssl=1)
Madrigal Pharmaceuticals Initiates NDA Rolling Submission for Breakthrough Liver Fibrosis Treatment - MyChesCo
![Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire](https://mms.businesswire.com/media/20220429005707/en/1438772/5/Biogen_Logo_Standard.jpg)